Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Analysts at HC Wainwright raised their FY2026 earnings estimates for Candel Therapeutics in a research note issued to investors on Friday, November 13th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($1.19) per share for the year, up from their prior estimate of ($1.28). HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock. The consensus estimate for Candel Therapeutics' current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Candel Therapeutics' Q4 2026 earnings at ($0.26) EPS, Q1 2027 earnings at ($0.30) EPS, Q2 2027 earnings at ($0.33) EPS, Q3 2027 earnings at ($0.33) EPS, FY2027 earnings at ($1.30) EPS, FY2028 earnings at ($0.89) EPS, FY2029 earnings at $0.60 EPS and FY2030 earnings at $1.31 EPS.
Candel Therapeutics (NASDAQ:CADL - Get Free Report) last released its quarterly earnings results on Friday, November 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.06.
Other research analysts also recently issued reports about the company. Citigroup lowered their target price on Candel Therapeutics from $26.00 to $20.00 and set a "buy" rating on the stock in a research note on Monday. Jefferies Financial Group assumed coverage on Candel Therapeutics in a research note on Thursday, October 22nd. They set a "buy" rating and a $25.00 price target for the company. Wall Street Zen downgraded Candel Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, August 16th. Stifel Nicolaus lowered their price objective on shares of Candel Therapeutics from $22.00 to $19.00 and set a "buy" rating on the stock in a research report on Friday. Finally, Canaccord Genuity Group dropped their price objective on shares of Candel Therapeutics from $25.00 to $13.00 and set a "buy" rating on the stock in a research note on Friday. Nine research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Candel Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $18.29.
View Our Latest Stock Report on Candel Therapeutics
Candel Therapeutics Stock Down 6.3%
CADL opened at $5.81 on Tuesday. The business has a 50 day moving average price of $9.61 and a two-hundred day moving average price of $8.39. The company has a quick ratio of 16.09, a current ratio of 16.09 and a debt-to-equity ratio of 0.38. The company has a market cap of $444.58 million, a PE ratio of -3.93 and a beta of -0.27. Candel Therapeutics has a 52 week low of $4.35 and a 52 week high of $14.00.
Hedge Funds Weigh In On Candel Therapeutics
A number of large investors have recently modified their holdings of CADL. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Candel Therapeutics in the 3rd quarter valued at approximately $41,000. Legal & General Group Plc acquired a new position in Candel Therapeutics during the second quarter worth $63,000. Cetera Investment Advisers acquired a new position in Candel Therapeutics during the third quarter worth $124,000. Renaissance Technologies LLC purchased a new position in Candel Therapeutics in the first quarter worth $63,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Candel Therapeutics by 19.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,962 shares of the company's stock valued at $152,000 after acquiring an additional 2,301 shares during the period. 13.93% of the stock is owned by hedge funds and other institutional investors.
Candel Therapeutics News Roundup
Here's some of the latest news about CADL:
- Positive Sentiment: Citigroup lowered its price target from $26 to $20 but maintained a Buy rating, implying substantial upside from the cited share price. Citigroup rating
- Positive Sentiment: A Seeking Alpha article describes an upgrade despite the filing delay, suggesting some investors see potential beyond the near-term setback. Seeking Alpha article
- Negative Sentiment: Levi & Korsinsky and Hagens Berman have announced investigations into whether Candel’s statements about the BLA timeline violated securities laws. These are allegations under investigation, not findings of wrongdoing, but add legal uncertainty. Levi & Korsinsky investigation notice
Candel Therapeutics Company Profile
(
Get Free Report)
Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company's clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Candel Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Candel Therapeutics wasn't on the list.
While Candel Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.